Gut epithelial barrier markers in patients with obstructive sleep apnea

Background: Obstructive sleep apnea (OSA) is now being recognized as an additional contributing factor to the pathogenesis of obesity-related comorbidities. At the same time, there is now increasing evidence to suggest that intestinal wall permeability plays a role in the development of metabolic sy...

Descripción completa

Detalles Bibliográficos
Autores: Barceló Bennasar, Antonia, Esquinas, Cristina, Robles, Juan, Pierola Lopetegui, Javier, de la Pena-Bravo, Monica, Aguilar, Irene, Morell Garcia, Danie, Alonso, Alberto, Toledo Pons, Nuria, Sanchez-de la Torre, Manuel, Barbe, Ferran
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/20314
Acceso en línea:http://hdl.handle.net/20.500.12105/20314
Access Level:acceso abierto
Palabra clave:Zonulin
Fatty acid binding protein (I-FABP)
Intestinal wall
Sleep apnea
Biomarcadores
Síndrome Metabólico
Femenino
Enfermedad del Hígado Graso no Alcohólico
Masculino
Circunferencia de la Cintura
Toxina del Cólera
Apnea Obstructiva del Sueño
Humanos
Persona de Mediana Edad
Obesidad
Alanina Transaminasa
Mucosa Intestinal
Proteínas de Unión a ácidos Grasos
Estudios Retrospectivos
Adulto
Absorción Intestinal
Estudios de Casos y Controles
Metabolic Syndrome
Case-Control Studies
Adult
Intestinal Absorption
Sleep Apnea, Obstructive
Cholera Toxin
Humans
Alanine Transaminase
Intestinal Mucosa
Middle Aged
Non-alcoholic Fatty Liver Disease
Obesity
Male
Biomarkers
Female
Fatty Acid-Binding Proteins
Waist Circumference
Retrospective Studies
Descripción
Sumario:Background: Obstructive sleep apnea (OSA) is now being recognized as an additional contributing factor to the pathogenesis of obesity-related comorbidities. At the same time, there is now increasing evidence to suggest that intestinal wall permeability plays a role in the development of metabolic syndrome. In the present study, circulating zonulin and fatty acid binding protein (I-FABP) were measured in association with metabolic, hepatic, and inflammatory parameters. Results: Compared with controls, plasma I-FABP levels were significantly higher in patients with OSA (571 pg/mL [IQR 290-950] vs 396 pg/mL [IQR 234-559], p = 0.04). Zonulin levels were similar between groups. Significant relationships were observed between zonulin levels and waist circumference (p < 0.05), glucose (p < 0.05), and insulin (p < 0.05). In addition, in the OSA group, zonulin levels correlated negatively with the mean nocturnal oxygenation saturation (p < 0.05) and positively with total cholesterol (p < 0.05), alanine aminotransferase (ALT) (p < 0.005), aminotransferase (AST) (p < 0.01), gamma glutamyltransferase (GGT) (p < 0.005), and high-sensitivity C-reactive protein (hs-CRP) (p < 0.05). Multivariate analysis showed that associations between zonulin and ALT, AST, and hs-CRP were attenuated, but not eliminated, after adjustment for other variables. Conclusions: The results of this study suggest that OSA is a risk factor for intestinal damage, regardless of metabolic profile, and that intestinal permeability might be a possible contributor to nonalcoholic fatty liver disease in patients with OSA.